OBLATH R W, GRIFFITH G C
Calif Med. 1960 Dec;93(6):343-6.
Development of the MAO-inhibitors has been an important advance in the treatment of tuberculosis, mental depression, several of the collagen diseases, hypertension and angina pectoris. Treatment must be carefully controlled and individualized. A sufficient number of MAO-inhibitors is available at present to afford ready and correct selection of the proper one for a given patient and disease. Provided such care is observed, treatment is most successful and side effects are few and, as a rule, readily corrected.
单胺氧化酶抑制剂的研制是治疗肺结核、精神抑郁症、几种胶原性疾病、高血压和心绞痛方面的一项重要进展。治疗必须严格控制并因人而异。目前已有足够数量的单胺氧化酶抑制剂可供使用，以便为特定的患者和疾病迅速且正确地选择合适的药物。只要遵循这种谨慎态度，治疗最为成功，副作用很少，而且通常很容易纠正。
